Gujarat Themis Biosyn Ltd.
NSE: GUJTHEM BSE: GUJTHEM
Prev Close
435.2
Open Price
433.3
Volume
29,002
Today Low / High
422 / 435.15
52 WK Low / High
208 / 479
Range
405 - 447
Prev Close
435.55
Open Price
433.35
Volume
4,740
Today Low / High
422.2 / 433.95
52 WK Low / High
192.35 / 479.45
Range
402 - 444
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 425.85 (target range: 405 - 447), reflecting a change of -9.35 (-2.14844%). On the BSE, it is listed at 423.15 (target range: 402 - 444), showing a change of -12.4 (-2.84698%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Gujarat Themis Biosyn Ltd. Graph
Gujarat Themis Biosyn Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Gujarat Themis Biosyn Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 425.85, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 423.15 | 427.38 | 384.64 - 470.12 |
| 431.61 | 345.29 - 517.94 | ||
| 435.84 | 305.09 - 566.60 | ||
| Bearish Scenario | 423.15 | 418.92 | 377.03 - 460.81 |
| 414.69 | 331.75 - 497.62 | ||
| 410.46 | 287.32 - 533.59 |
Overview of Gujarat Themis Biosyn Ltd.
ISIN
INE942C01045
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
186,888
Market Cap
46,402,858,100
Last Dividend
0.67
Official Website
IPO Date
2025-02-25
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of GUJTHEM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-04 | September 04, 25 | 0.67 | 0.67 | 2025-09-05 | 2025-10-12 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 150.79 Cr | 31.88 Cr | 118.91 Cr | 0.7886 | 3.44 Cr | 2.35 Cr | 64.25 Cr | 48.77 Cr | 4.48 | 71.42 Cr | 0.3234 |
| 2024-03-31 | 169.81 Cr | 41.61 Cr | 128.20 Cr | 0.7550 | 3.90 Cr | 1.45 Cr | 75.55 Cr | 59.16 Cr | 5.43 | 83.54 Cr | 0.3484 |
| 2023-03-31 | 148.13 Cr | 30.78 Cr | 117.35 Cr | 0.7922 | 2.93 Cr | 1.44 Cr | 72.51 Cr | 57.97 Cr | 5.32 | 80.14 Cr | 0.3913 |
| 2022-03-31 | 114.19 Cr | 20.89 Cr | 93.30 Cr | 0.8170 | 0.45 Cr | 0.83 Cr | 56.57 Cr | 43.62 Cr | 4.00 | 62.00 Cr | 0.3820 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial balance sheet data available. | ||||||||||||
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial cash flow statement data available. | |||||||||||
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 42.35 Cr | 7.44 Cr | 34.91 Cr | 0.8244 | 17.98 Cr | 14.26 Cr | 1.31 | 21.76 Cr | 0.3368 |
| 2025-06-30 | 35.87 Cr | 8.00 Cr | 27.88 Cr | 0.7771 | 11.89 Cr | 9.06 Cr | 0.83 | 14.20 Cr | 0.2526 |
| 2025-03-31 | 37.72 Cr | 8.35 Cr | 29.37 Cr | 0.7787 | 15.59 Cr | 12.00 Cr | 0.00 | 17.26 Cr | 0.3180 |
| 2024-12-31 | 39.52 Cr | 8.86 Cr | 30.66 Cr | 0.7758 | 17.30 Cr | 12.97 Cr | 1.19 | 19.11 Cr | 0.3282 |
| 2024-09-30 | 34.72 Cr | 6.88 Cr | 27.83 Cr | 0.8018 | 13.96 Cr | 10.57 Cr | 0.97 | 15.71 Cr | 0.3044 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 6.36 Cr | 4.03 Cr | 10.38 Cr | 35.15 Cr | 7.21 Cr | 54.80 Cr | 294.29 Cr | 376.67 Cr | 112.24 Cr |
| 2025-03-31 | 11.69 Cr | 1.85 Cr | 11.69 Cr | 31.45 Cr | 5.05 Cr | 51.97 Cr | 246.50 Cr | 301.31 Cr | 52.93 Cr |
| 2024-09-30 | 8.38 Cr | 9.73 Cr | 18.11 Cr | 28.57 Cr | 4.64 Cr | 52.25 Cr | 178.61 Cr | 248.15 Cr | 24.72 Cr |
| 2024-03-31 | 6.47 Cr | 7.66 Cr | 14.13 Cr | 27.59 Cr | 3.33 Cr | 47.56 Cr | 136.64 Cr | 221.11 Cr | 19.74 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,728.90 | ₹4,148,210,229,633.00 | ₹1,416,681.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,363.50 | ₹1,689,309,308,830.00 | ₹145,449.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,869.80 | ₹1,309,716,163,712.00 | ₹100,222.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,250.00 | ₹1,040,640,656,250.00 | ₹1,184,276.00 |
| Lupin Limited | LUPIN | ₹2,083.70 | ₹951,831,672,062.00 | ₹574,147.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹921.95 | ₹927,697,427,081.00 | ₹442,181.00 |
| Mankind Pharma Limited | MANKIND | ₹2,195.00 | ₹906,107,133,040.00 | ₹161,264.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,207.40 | ₹701,259,879,610.00 | ₹644,055.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,552.50 | ₹663,884,662,500.00 | ₹42,044.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,103.20 | ₹595,569,781,262.00 | ₹1,017,039.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,039.20 | ₹575,463,889,713.00 | ₹333,641.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,912.80 | ₹363,912,485,587.00 | ₹152,336.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,413.00 | ₹358,484,060,034.00 | ₹118,954.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,840.20 | ₹288,269,089,231.00 | ₹131,618.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,489.50 | ₹282,368,298,330.00 | ₹540,896.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,452.40 | ₹236,003,626,256.00 | ₹1,876,440.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,438.00 | ₹210,950,000,000.00 | ₹30,842.00 |
| Eris Lifesciences Limited | ERIS | ₹1,542.00 | ₹210,046,445,922.00 | ₹100,879.00 |
| Cohance Lifesciences Limited | COHANCE | ₹513.20 | ₹196,333,456,248.00 | ₹1,497,648.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,040.00 | ₹192,961,530,560.00 | ₹21,999.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,070.60 | ₹169,688,424,511.00 | ₹73,556.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹837.50 | ₹164,621,616,350.00 | ₹61,314.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹906.10 | ₹162,291,453,207.00 | ₹580,632.00 |
| Granules India Limited | GRANULES | ₹605.25 | ₹146,875,240,359.00 | ₹476,877.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,845.30 | ₹140,264,382,629.00 | ₹55,819.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹898.60 | ₹110,241,459,313.00 | ₹28,862.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,844.00 | ₹97,006,788,408.00 | ₹8,065.00 |
| Strides Pharma Science Limited | STAR | ₹950.65 | ₹87,623,990,564.00 | ₹448,112.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹447.35 | ₹68,490,205,646.00 | ₹65,586.00 |
| FDC Limited | FDC | ₹412.90 | ₹67,224,283,684.00 | ₹71,330.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹730.65 | ₹66,231,445,361.00 | ₹112,145.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹317.00 | ₹61,999,435,672.00 | ₹188,272.00 |
| Sequent Scientific Limited | SEQUENT | ₹206.94 | ₹51,698,541,104.00 | ₹527,547.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹425.85 | ₹46,402,858,100.00 | ₹29,002.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹135.34 | ₹43,920,751,720.00 | ₹567,336.00 |
| Innova Captab Limited | INNOVACAP | ₹733.20 | ₹41,957,317,943.00 | ₹22,643.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹785.20 | ₹39,824,641,246.00 | ₹133,295.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,302.00 | ₹38,072,812,530.00 | ₹5,519.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹404.95 | ₹36,959,786,500.00 | ₹87,551.00 |
| Suven Life Sciences Limited | SUVEN | ₹161.92 | ₹35,688,141,949.00 | ₹189,272.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹332.65 | ₹33,358,975,621.00 | ₹17,408.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹433.85 | ₹30,545,534,638.00 | ₹18,863.00 |
Key Executives
Gender: Not Specified
Year Born: 1975
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1954
Gender: male
Year Born:
Gender: female
Year Born:
FAQs about Gujarat Themis Biosyn Ltd.
The CEO is Sachin Dinesh Patel.
The current price is ₹425.85.
The range is ₹208-479.
The market capitalization is ₹4,640.29 crores.
The dividend yield is 0.16%.
The P/E ratio is 96.01.
The company operates in the Healthcare sector.
Overview of Gujarat Themis Biosyn Ltd. (ISIN: INE942C01045) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹4,640.29 crores and an average daily volume of 186,888 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.67.